258 related articles for article (PubMed ID: 36807817)
1. A Review of FXIa Inhibition as a Novel Target for Anticoagulation.
Koulas I; Spyropoulos AC
Hamostaseologie; 2023 Feb; 43(1):28-36. PubMed ID: 36807817
[TBL] [Abstract][Full Text] [Related]
2. Asundexian: an oral small molecule factor XIa inhibitor for the treatment of thrombotic disorders.
D'Allesandro N; Cave B; Hough A
Future Cardiol; 2023 Aug; 19(10):477-486. PubMed ID: 37830334
[TBL] [Abstract][Full Text] [Related]
3. Targeting factor XI and factor XIa to prevent thrombosis.
Gailani D; Gruber A
Blood; 2024 Apr; 143(15):1465-1475. PubMed ID: 38142404
[TBL] [Abstract][Full Text] [Related]
4. Unresolved issues in the use of direct acting oral anticoagulants.
Chan N; Hirsh J
Expert Rev Cardiovasc Ther; 2023; 21(12):913-921. PubMed ID: 37837206
[TBL] [Abstract][Full Text] [Related]
5. An update on antithrombotic therapy in atrial fibrillation: the role of newer and emergent drugs.
Deedwania P; Huang GW
Rev Cardiovasc Med; 2012; 13(2-3):e89-104. PubMed ID: 23160166
[TBL] [Abstract][Full Text] [Related]
6. Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week.
Harrington J; Piccini JP; Alexander JH; Granger CB; Patel MR
J Am Coll Cardiol; 2023 Feb; 81(8):771-779. PubMed ID: 36813377
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
8. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Piccini JP; Lopes RD; Mahaffey KW
Curr Opin Cardiol; 2010 Jul; 25(4):312-20. PubMed ID: 20520539
[TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
Perales IJ; San Agustin K; DeAngelo J; Campbell AM
Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
[No Abstract] [Full Text] [Related]
10. Oral Anticoagulant Use in Morbid Obesity and Post Bariatric Surgery: A Review.
Nasser MF; Jabri A; Gandhi S; Rader F
Am J Med; 2021 Dec; 134(12):1465-1475. PubMed ID: 34403701
[TBL] [Abstract][Full Text] [Related]
11. Factor XI as a Therapeutic Target.
Gailani D; Gruber A
Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1316-22. PubMed ID: 27174099
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulation Therapy and NOACs in Heart Failure.
Thomas I; EncisoSilva J; Schlueter M; Greenberg B
Handb Exp Pharmacol; 2017; 243():515-535. PubMed ID: 28233177
[TBL] [Abstract][Full Text] [Related]
13. Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.
McCarty D; Robinson A
Ther Adv Cardiovasc Dis; 2016 Feb; 10(1):37-49. PubMed ID: 26378211
[TBL] [Abstract][Full Text] [Related]
14. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
15. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
Becattini C; Vedovati MC; Agnelli G
Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937
[TBL] [Abstract][Full Text] [Related]
16. Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
Marcy TR; Truong T; Rai A
Consult Pharm; 2015 Nov; 30(11):644-56. PubMed ID: 26629800
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the discovery and development of factor XI/XIa inhibitors.
Al-Horani RA; Afosah DK
Med Res Rev; 2018 Sep; 38(6):1974-2023. PubMed ID: 29727017
[TBL] [Abstract][Full Text] [Related]
18. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Arepally GM; Ortel TL
Annu Rev Med; 2015; 66():241-53. PubMed ID: 25587651
[TBL] [Abstract][Full Text] [Related]
19. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
Hohnloser SH; Fudim M; Alexander JH; Wojdyla DM; Ezekowitz JA; Hanna M; Atar D; Hijazi Z; Bahit MC; Al-Khatib SM; Lopez-Sendon JL; Wallentin L; Granger CB; Lopes RD
Circulation; 2019 May; 139(20):2292-2300. PubMed ID: 30773022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
